Evidence map›Paper›PMID 28860350›Full record

ArticleGut2018

Identification of distinct mutational patterns and new driver genes in oesophageal squamous cell carcinomas and adenocarcinomas.

De-Chen Lin, Huy Q Dinh, Jian-Jun Xie, Anand Mayakonda, Tiago Chedraoui Silva, Yan-Yi Jiang, Ling-Wen Ding, Jian-Zhong He, Xiu-E Xu, Jia-Jie Hao and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 1 synthesis or guideline pooled it, 126 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Molecular subtyping-guided precision therapy for ESCC: biomarker-driven strategies and clinical translation pathways.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Archives of medical science : AMS · 2025
    Article
  16. ElevatedJournal of thoracic disease · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. A druggable cascade links methionine metabolism to epigenomic reprogramming in squamous cell carcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

De-Chen Lin *Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Huy Q Dinh *Center for Bioinformatics and Functional Genomics, Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Jian-Jun Xie *Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Anand Mayakonda *Cancer Science Institute of Singapore, National University of Singapore, Singapore.
Tiago Chedraoui SilvaCenter for Bioinformatics and Functional Genomics, Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Yan-Yi JiangCancer Science Institute of Singapore, National University of Singapore, Singapore.
Ling-Wen DingCancer Science Institute of Singapore, National University of Singapore, Singapore.
Jian-Zhong HeDepartment of Biochemistry and Molecular Biology, Medical College of Shantou University, Shantou, China.
Xiu-E XuDepartment of Biochemistry and Molecular Biology, Medical College of Shantou University, Shantou, China.
Jia-Jie HaoState Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ming-Rong WangState Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Chunquan LiDepartment of Biochemistry and Molecular Biology, Medical College of Shantou University, Shantou, China.
Li-Yan XuDepartment of Biochemistry and Molecular Biology, Medical College of Shantou University, Shantou, China.
En-Min LiDepartment of Biochemistry and Molecular Biology, Medical College of Shantou University, Shantou, China.
Benjamin P BermanCenter for Bioinformatics and Functional Genomics, Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
H Phillip KoefflerDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Cedars-Sinai Medical Center · USShantou University · CNShantou University Medical College · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNNational University Cancer Institute, Singapore · SGNational University of Singapore · SG

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Pilot and Feasibility ProgramP30DK041301 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 1990 to 2019
$18.0M
Statistical Analysis of Epigenomics DataR01HG006705 · NHGRI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SIEGMUND, KIMBERLY D · 2013 to 2015
$1.1M
NCATS NIH HHS UL1 TR000124NHGRI NIH HHS R01 HG006705NIDDK NIH HHS P30 DK041301
6 · The paper itself

Abstract

objectivesOesophageal squamous cell carcinoma (OSCC) and adenocarcinoma (OAC) are distinct cancers in terms of a number of clinical and epidemiological characteristics, complicating the design of clinical trials and biomarker developments. We analysed 1048 oesophageal tumour-germline pairs from both subtypes, to characterise their genomic features, and biological and clinical significance.

designPreviously exome-sequenced samples were re-analysed to identify significantly mutated genes (SMGs) and mutational signatures. The biological functions of novel SMGs were investigated using cell line and xenograft models. We further performed whole-genome bisulfite sequencing and chromatin immunoprecipitation (ChIP)-seq to characterise epigenetic alterations.

resultsOSCC and OAC displayed nearly mutually exclusive sets of driver genes, indicating that they follow independent developmental paths. The combined sample size allowed the statistical identification of a number of novel subtype-specific SMGs, mutational signatures and prognostic biomarkers. Particularly, we identified a novel mutational signature similar to Catalogue Of Somatic Mutations In Cancer (COSMIC)signature 16, which has prognostic value in OSCC. Two newly discovered SMGs,

conclusionsThese data comprehensively contrast differences between OSCC and OAC at both genomic and epigenomic levels, and reveal novel molecular features for further delineating the pathophysiological mechanisms and treatment strategies for these cancers.

Indexed as

AdenocarcinomaAnimalsCarcinoma, Squamous CellCell Line, TumorCell ProliferationCullin ProteinsDNA MethylationEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaHumansLoss of Function MutationPrognosisTranscription FactorsCUL3 protein, humanCullin ProteinsTranscription FactorsZFP36L2 protein, humangene mutationmethylationoesophageal cancer

Identifiers

PMID28860350
PMCPMC5980794
OpenAlexW2753687033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.